BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yeung YP, Lo CM, Liu CL, Wong BC, Fan ST, Wong J. Natural history of untreated nonsurgical hepatocellular carcinoma. Am J Gastroenterol. 2005;100:1995-2004. [PMID: 16128944 DOI: 10.1111/j.1572-0241.2005.00229.x] [Cited by in Crossref: 100] [Cited by in F6Publishing: 95] [Article Influence: 5.9] [Reference Citation Analysis]
Number Citing Articles
1 El-serag HB, Lechel A, Rudolph KL. Epidemiology and Molecular Mechanisms of Hepatocarcinogenesis. Zakim and Boyer's Hepatology. Elsevier; 2012. pp. 142-56. [DOI: 10.1016/b978-1-4377-0881-3.00010-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Lin CY, Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC. Is the Cancer of the Liver Italian Program system an adequate weighting for survival of hepatocellular carcinoma? Evaluation of intrascore prognostic value among 36 subgroups. Liver Int. 2009;29:74-81. [PMID: 18331238 DOI: 10.1111/j.1478-3231.2008.01702.x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
3 Cunningham SC, Choti MA, Bellavance EC, Pawlik TM. Palliation of hepatic tumors. Surgical Oncology 2007;16:277-91. [DOI: 10.1016/j.suronc.2007.08.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
4 Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol. 2010;21:1024-1030. [PMID: 20621715 DOI: 10.1016/j.jvir.2010.03.005] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.7] [Reference Citation Analysis]
5 Mizumoto M, Oshiro Y, Okumura T, Fukuda K, Fukumitsu N, Abei M, Ishikawa H, Ohnishi K, Numajiri H, Tsuboi K, Sakurai H. Association between pretreatment retention rate of indocyanine green 15 min after administration and life prognosis in patients with HCC treated by proton beam therapy. Radiother Oncol 2014;113:54-9. [PMID: 25248924 DOI: 10.1016/j.radonc.2014.08.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
6 Tu T, Budzinska MA, Maczurek AE, Cheng R, Di Bartolomeo A, Warner FJ, McCaughan GW, McLennan SV, Shackel NA. Novel aspects of the liver microenvironment in hepatocellular carcinoma pathogenesis and development. Int J Mol Sci. 2014;15:9422-9458. [PMID: 24871369 DOI: 10.3390/ijms15069422] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
7 Buijs M, Reyes DK, Pawlik TM, Blackford AL, Salem R, Messersmith WA, Weekes CD, Mulcahy M, Kamel IR, Geschwind JF. Phase 2 trial of concurrent bevacizumab and transhepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer. 2013;119:1042-1049. [PMID: 23132335 DOI: 10.1002/cncr.27859] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
8 Díaz Sánchez A, Núñez Martínez O, Prieto Martín M, Beceiro Pedreño I, Calleja Kempin J, Santos Castro L, Muro de la Fuente A, Clemente Ricote G, Matilla Peña A. [Prognostic factors in patients with non-active treatment of hepatocellular carcinoma]. Gastroenterol Hepatol 2007;30:441-8. [PMID: 17949609 DOI: 10.1157/13110488] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Kouloulias V, Mosa E, Georgakopoulos J, Platoni K, Brountzos I, Zygogianni A, Antypas C, Kosmidis P, Mystakidou K, Tolia M. Three-dimensional conformal radiotherapy for hepatocellular carcinoma in patients unfit for resection, ablation, or chemotherapy: a retrospective study. ScientificWorldJournal. 2013;2013:780141. [PMID: 24379750 DOI: 10.1155/2013/780141] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
10 Yoo JJ, Lee DH, Cho Y, Cho EJ, Lee JH, Yu SJ, Kim YJ, Kim CY, Yoon JH. Differential sensitivity of hepatocellular carcinoma cells to suppression of hepatocystin transcription under hypoxic conditions. J Bioenerg Biomembr 2016;48:581-90. [PMID: 27640193 DOI: 10.1007/s10863-016-9677-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
11 Zeeneldin AA, Salem SE, Darwish AD, El-Gammal MM, Hussein MM, Saadeldin M. Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. J Hepatocell Carcinoma 2015;2:3-9. [PMID: 27508189 DOI: 10.2147/JHC.S73828] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
12 Aghoram R, Cai P, Dickinson JA. Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis B. Cochrane Database Syst Rev 2012;:CD002799. [PMID: 22972059 DOI: 10.1002/14651858.CD002799.pub2] [Cited by in Crossref: 21] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
13 Chen P, Furuse J, Han K, Hsu C, Lim H, Moon H, Qin S, Ye S, Yeoh E, Yeo W. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion: HCC clinical trials in Asia. Liver International 2010;30:1427-38. [DOI: 10.1111/j.1478-3231.2010.02292.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
14 Lin CC, Hung CF, Chen WT, Lin SM. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Impact of Early Response to 4 Weeks of Treatment. Liver Cancer 2015;4:228-40. [PMID: 26734578 DOI: 10.1159/000367737] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kim TH, Kim DY, Park JW, Kim YI, Kim SH, Park HS, Lee WJ, Park SJ, Hong EK, Kim CM. Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable. Am J Clin Oncol. 2006;29:568-575. [PMID: 17148993 DOI: 10.1097/01.coc.0000239147.60196.11] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 4.9] [Reference Citation Analysis]
16 Huang D, Zhang W, Huang D, Wu J. Antitumor activity of the aqueous extract from Sedum sarmentosum Bunge in vitro. Cancer Biother Radiopharm. 2010;25:81-88. [PMID: 20187800 DOI: 10.1089/cbr.2009.0632] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
17 Cheng AL, Guan Z, Chen Z, Tsao CJ, Qin S, Kim JS, Yang TS, Tak WY, Pan H, Yu S, Xu J, Fang F, Zou J, Lentini G, Voliotis D, Kang YK. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012;48:1452-1465. [PMID: 22240282 DOI: 10.1016/j.ejca.2011.12.006] [Cited by in Crossref: 166] [Cited by in F6Publishing: 160] [Article Influence: 16.6] [Reference Citation Analysis]
18 Chapman BC, Paniccia A, Hosokawa PW, Henderson WG, Overbey DM, Messersmith W, McCarter MD, Gleisner A, Edil BH, Schulick RD, Gajdos C. Impact of Facility Type and Surgical Volume on 10-Year Survival in Patients Undergoing Hepatic Resection for Hepatocellular Carcinoma. J Am Coll Surg 2017;224:362-72. [PMID: 27923615 DOI: 10.1016/j.jamcollsurg.2016.11.011] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
19 Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis 2010;42 Suppl 3:S206-14. [PMID: 20547305 DOI: 10.1016/S1590-8658(10)60507-5] [Cited by in Crossref: 347] [Cited by in F6Publishing: 196] [Article Influence: 28.9] [Reference Citation Analysis]
20 Altomonte J, Wu L, Chen L, Meseck M, Ebert O, García-Sastre A, Fallon J, Woo SL. Exponential enhancement of oncolytic vesicular stomatitis virus potency by vector-mediated suppression of inflammatory responses in vivo. Mol Ther 2008;16:146-53. [PMID: 18071337 DOI: 10.1038/sj.mt.6300343] [Cited by in Crossref: 54] [Cited by in F6Publishing: 51] [Article Influence: 3.6] [Reference Citation Analysis]
21 Tajiri H, Tanaka H, Brooks S, Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control. 2011;22:523-527. [PMID: 21191808 DOI: 10.1007/s10552-010-9721-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
22 Kasai K, Ushio A, Kasai Y, Sawara K, Miyamoto Y, Oikawa K, Kuroda H, Takikawa Y, Suzuki K. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012;118:3302-3310. [PMID: 22072099 DOI: 10.1002/cncr.26648] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
23 Kee KM, Wang JH, Lee CM, Chen CL, Changchien CS, Hu TH, Cheng YF, Hsu HC, Wang CC, Chen TY, Lin CY, Lu SN. Validation of clinical AJCC/UICC TNM staging system for hepatocellular carcinoma: analysis of 5,613 cases from a medical center in southern Taiwan. Int J Cancer. 2007;120:2650-2655. [PMID: 17304512 DOI: 10.1002/ijc.22616] [Cited by in Crossref: 74] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
24 Meng XY, Zhang XP, Sun Z, Wang HQ, Yu WF. Distant survival for patients undergoing surgery using volatile versus IV anesthesia for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study. BMC Anesthesiol 2020;20:233. [PMID: 32928121 DOI: 10.1186/s12871-020-01111-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
25 Zhao G, Cui J, Qin Q, Zhang J, Liu L, Deng S, Wu C, Yang M, Li S, Wang C. Mechanical stiffness of liver tissues in relation to integrin β1 expression may influence the development of hepatic cirrhosis and hepatocellular carcinoma. J Surg Oncol 2010;102:482-9. [PMID: 20872952 DOI: 10.1002/jso.21613] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 3.1] [Reference Citation Analysis]
26 Huo TI, Huang YH, Chiang JH, Wu JC, Lee PC, Chi CW, Lee SD. Survival impact of delayed treatment in patients with hepatocellular carcinoma undergoing locoregional therapy: is there a lead-time bias? Scand J Gastroenterol 2007;42:485-92. [PMID: 17454859 DOI: 10.1080/00365520600931402] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
27 Bruix J, Raoul JL, Sherman M, Mazzaferro V, Bolondi L, Craxi A, Galle PR, Santoro A, Beaugrand M, Sangiovanni A, Porta C, Gerken G, Marrero JA, Nadel A, Shan M, Moscovici M, Voliotis D, Llovet JM. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol. 2012;57:821-829. [PMID: 22727733 DOI: 10.1016/j.jhep.2012.06.014] [Cited by in Crossref: 473] [Cited by in F6Publishing: 467] [Article Influence: 47.3] [Reference Citation Analysis]
28 Giannini EG, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL, Di Marco M, Benvegnù L, Caturelli E, Zoli M, Borzio F, Chiaramonte M, Trevisani F; for the Italian Liver Cancer (ITA.LI.CA) group. Prognosis of untreated hepatocellular carcinoma. Hepatology 2015;61:184-90. [DOI: 10.1002/hep.27443] [Cited by in Crossref: 87] [Cited by in F6Publishing: 89] [Article Influence: 10.9] [Reference Citation Analysis]
29 Choi Y, Kim JW, Cha H, Han KH, Seong J. Overall response of both intrahepatic tumor and portal vein tumor thrombosis is a good prognostic factor for hepatocellular carcinoma patients receiving concurrent chemoradiotherapy. J Radiat Res 2014;55:113-20. [PMID: 23772086 DOI: 10.1093/jrr/rrt082] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
30 Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34. [PMID: 19095497 DOI: 10.1016/s1470-2045(08)70285-7] [Cited by in Crossref: 3367] [Cited by in F6Publishing: 1875] [Article Influence: 240.5] [Reference Citation Analysis]
31 McKinley SK, Chawla A, Ferrone CR. Inoperable Biliary Tract and Primary Liver Tumors: Palliative Treatment Options. Surg Oncol Clin N Am 2019;28:745-62. [PMID: 31472917 DOI: 10.1016/j.soc.2019.06.009] [Reference Citation Analysis]
32 Xing M, Kokabi N, Camacho JC, Kim HS. Prospective longitudinal quality of life and survival outcomes in patients with advanced infiltrative hepatocellular carcinoma and portal vein thrombosis treated with Yttrium-90 radioembolization. BMC Cancer 2018;18:75. [PMID: 29329568 DOI: 10.1186/s12885-017-3921-1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
33 Katamura Y, Aikata H, Takaki S, Azakami T, Kawaoka T, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Kenjo M, Toyota N, Ito K, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for advanced hepatocellular carcinoma with or without three-dimensional conformal radiotherapy for portal vein tumor thrombosis. J Gastroenterol. 2009;44:492-502. [PMID: 19330281 DOI: 10.1007/s00535-009-0033-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.2] [Reference Citation Analysis]
34 Tsai AL, Burke CT, Kennedy AS, Moore DT, Mauro MA, Dixon RD, Stavas JM, Bernard SA, Khandani AH, O’Neil BH. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21:1377-1384. [PMID: 20691606 DOI: 10.1016/j.jvir.2010.04.027] [Cited by in Crossref: 34] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
35 Xiao L, Fu ZR, Ding GS, Fu H, Ni ZJ, Wang ZX, Shi XM, Guo WY. Liver transplantation for hepatitis B virus-related hepatocellular carcinoma: one center’s experience in China. Transplant Proc. 2009;41:1717-1721. [PMID: 19545714 DOI: 10.1016/j.transproceed.2009.03.058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
36 Bell R, Pandanaboyana S, Lodge JPA, Prasad KR, Jones R, Hidalgo E. Primary liver resection for patients with cirrhosis and hepatocellular carcinoma: the role of surgery in BCLC early (A) and intermediate stages (B). Langenbecks Arch Surg. 2017;402:575-583. [PMID: 27456677 DOI: 10.1007/s00423-016-1475-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
37 Chen MY, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Tsang NM, Chan KM, Lee WC. Efficacy of External Beam Radiation-Based Treatment plus Locoregional Therapy for Hepatocellular Carcinoma Associated with Portal Vein Tumor Thrombosis. Biomed Res Int 2016;2016:6017406. [PMID: 27999803 DOI: 10.1155/2016/6017406] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
38 Tandon P, Garcia-Tsao G. Prognostic indicators in hepatocellular carcinoma: a systematic review of 72 studies. Liver Int. 2009;29:502-510. [PMID: 19141028 DOI: 10.1111/j.1478-3231.2008.01957.x] [Cited by in Crossref: 199] [Cited by in F6Publishing: 200] [Article Influence: 14.2] [Reference Citation Analysis]
39 Zhang Q, Bai XL, Chen W, Ma T, Liu H, Zhang Y, Hu XJ, Liang TB; Cochrane Hepato-Biliary Group. Postoperative adjuvant transarterial (chemo)embolisation after liver resection for hepatocellular carcinoma. Cochrane Database of Systematic Reviews. [DOI: 10.1002/14651858.cd010897] [Reference Citation Analysis]
40 Kim DY, Han KH. How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage. Dig Dis 2012;30:598-602. [PMID: 23258101 DOI: 10.1159/000343088] [Cited by in Crossref: 12] [Cited by in F6Publishing: 63] [Article Influence: 1.2] [Reference Citation Analysis]
41 Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer. 2008;113:995-1003. [PMID: 18615601 DOI: 10.1002/cncr.23684] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
42 Sarpel U, Ayo D, Lobach I, Xu R, Newman E. Inverse relationship between cirrhosis and massive tumours in hepatocellular carcinoma. HPB (Oxford). 2012;14:741-745. [PMID: 23043662 DOI: 10.1111/j.1477-2574.2012.00507.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
43 Sharr WW, Chan SC, Lo CM. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation. Transplantation. 2014;97 Suppl 8:S10-S17. [PMID: 24849822 DOI: 10.1097/01.tp.0000446267.19148.21] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
44 Shi M, Chen JA, Lin XJ, Guo RP, Yuan YF, Chen MS, Zhang YQ, Li JQ. Transarterial chemoembolization as initial treatment for unresectable hepatocellular carcinoma in southern China. World J Gastroenterol 2010; 16(2): 264-269 [PMID: 20066748 DOI: 10.3748/wjg.v16.i2.264] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
45 Tu HAT, Woerdenbag HJ, Riewpaiboon A, Kane S, Le DM, Postma MJ, Li SC. Cost of Illness of Chronic Hepatitis B Infection in Vietnam. Value Health Reg Issues 2012;1:23-8. [PMID: 29702821 DOI: 10.1016/j.vhri.2012.03.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
46 Khalaf N, Ying J, Mittal S, Temple S, Kanwal F, Davila J, El-Serag HB. Natural History of Untreated Hepatocellular Carcinoma in a US Cohort and the Role of Cancer Surveillance. Clin Gastroenterol Hepatol 2017;15:273-281.e1. [PMID: 27521507 DOI: 10.1016/j.cgh.2016.07.033] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 9.8] [Reference Citation Analysis]
47 Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma: Current management. Curr Probl Surg. 2010;47:10-67. [PMID: 19963083 DOI: 10.1067/j.cpsurg.2009.09.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 4.7] [Reference Citation Analysis]
48 Muñoz-Álvarez KA, Altomonte J, Laitinen I, Ziegler S, Steiger K, Esposito I, Schmid RM, Ebert O. PET imaging of oncolytic VSV expressing the mutant HSV-1 thymidine kinase transgene in a preclinical HCC rat model. Mol Ther 2015;23:728-36. [PMID: 25609160 DOI: 10.1038/mt.2015.12] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
49 Chuma M, Taguchi H, Yamamoto Y, Shimizu S, Nakanishi M, Ogawa K, Sho T, Horimoto H, Kobayashi T, Nakai M. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol. 2011;26:1123-1132. [PMID: 21501224 DOI: 10.1111/j.1440-1746.2011.06745.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
50 de Villa V, Lo CM. Liver transplantation for hepatocellular carcinoma in Asia. Oncologist. 2007;12:1321-1331. [PMID: 18055852 DOI: 10.1634/theoncologist.12-11-1321] [Cited by in Crossref: 81] [Cited by in F6Publishing: 82] [Article Influence: 5.8] [Reference Citation Analysis]
51 Park UJ, Kim YH, Kang KJ, Lim TJ. [Risk factors for early recurrence after surgical resection for hepatocellular carcinoma]. Korean J Hepatol. 2008;14:371-380. [PMID: 18815460 DOI: 10.3350/kjhep.2008.14.3.371] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
52 Soni S, Pareek P, Narayan S, Rakesh A, Abhilasha A. Hepatocellular Carcinoma (HCC) in North-Western India: A Retrospective Study Focusing on Epidemiology, Risk Factors, and Survival. J Gastrointest Cancer 2021. [PMID: 34550547 DOI: 10.1007/s12029-021-00712-z] [Reference Citation Analysis]
53 Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol. 2012;8:164-171. [PMID: 22524575 DOI: 10.1111/j.1743-7563.2012.01543.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
54 Zhu Y, Dong M, Yang J, Zhang J. Evaluation of Iodine-125 Interstitial Brachytherapy Using Micro-Positron Emission Tomography/Computed Tomography with 18F-Fluorodeoxyglucose in Hepatocellular Carcinoma HepG2 Xenografts. Med Sci Monit 2019;25:371-80. [PMID: 30636171 DOI: 10.12659/MSM.912590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
55 Sarpel U, Spivack JH, Berger Y, Heskel M, Aycart SN, Sweeney R, Edwards MP, Labow DM, Kim E. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib. HPB (Oxford) 2016;18:411-8. [PMID: 27154804 DOI: 10.1016/j.hpb.2016.02.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
56 Man YN, Liu XH, Wu XZ. Chinese medicine herbal treatment based on syndrome differentiation improves the overall survival of patients with unresectable hepatocellular carcinoma. Chin J Integr Med 2015;21:49-57. [PMID: 25533651 DOI: 10.1007/s11655-014-1767-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
57 Han DH, Joo DJ, Kim MS, Choi GH, Choi JS, Park YN, Seong J, Han KH, Kim SI. Living Donor Liver Transplantation for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis after Concurrent Chemoradiation Therapy. Yonsei Med J. 2016;57:1276-1281. [PMID: 27401662 DOI: 10.3349/ymj.2016.57.5.1276] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
58 Chen G, Zhang J, Sun J, Wei S, Chen J, Ren H, Zhou S. Revisiting Partial Hepatectomy of Large Hepatocellular Carcinoma in Older Patients. Sci Rep 2018;8:14505. [PMID: 30266965 DOI: 10.1038/s41598-018-32798-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012; 18(26): 3426-3434 [PMID: 22807613 DOI: 10.3748/wjg.v18.i26.3426] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
60 Kim MN, Kim BK, Han KH. Hepatocellular carcinoma in patients with chronic hepatitis C virus infection in the Asia-Pacific region. J Gastroenterol 2013;48:681-8. [PMID: 23463401 DOI: 10.1007/s00535-013-0770-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 3.7] [Reference Citation Analysis]
61 Lee HL, Tsai JT, Chen CY, Lin YC, Ho CB, Ting LL, Kuo CC, Lai IC, Lin CY, Tang JH, Huang YM, Kao WY, Cheng SW, Shen CN, Chen SW, Chiou JF. Effectiveness of stereotactic ablative radiotherapy in patients with advanced hepatocellular carcinoma unsuitable for transarterial chemoembolization. Ther Adv Med Oncol 2019;11:1758835919889002. [PMID: 31839809 DOI: 10.1177/1758835919889002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
62 Kim Y, Stahl CC, Makramalla A, Olowokure OO, Ristagno RL, Dhar VK, Schoech MR, Chadalavada S, Latif T, Kharofa J, Bari K, Shah SA. Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria. Surgery. 2017;162:1250-1258. [PMID: 29033224 DOI: 10.1016/j.surg.2017.08.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
63 Katamura Y, Aikata H, Kimura Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Kawakami Y, Takahashi S, Ishikawa M, Hieda M, Kakizawa H, Chayama K. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases: Chemotherapy for hepatoma. Journal of Gastroenterology and Hepatology 2010;25:1117-22. [DOI: 10.1111/j.1440-1746.2009.06110.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
64 Song P, Hai Y, Ma W, Zhao L, Wang X, Xie Q, Li Y, Wu Z, Li Y, Li H. Arsenic trioxide combined with transarterial chemoembolization for unresectable primary hepatic carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2018;97:e0613. [PMID: 29718867 DOI: 10.1097/MD.0000000000010613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
65 Zhang YA, Zhu CW. Management of advanced hepatocellular carcinoma. Shijie Huaren Xiaohua Zazhi 2010; 18(12): 1250-1254 [DOI: 10.11569/wcjd.v18.i12.1250] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
66 Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J Viral Hepat. 2009;16:453-463. [PMID: 19302335 DOI: 10.1111/j.1365-2893.2009.01117.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 198] [Article Influence: 14.2] [Reference Citation Analysis]
67 Zhang XB, Wang JH, Yan ZP, Qian S, Du SS, Zeng ZC. Hepatocellular carcinoma with main portal vein tumor thrombus: treatment with 3-dimensional conformal radiotherapy after portal vein stenting and transarterial chemoembolization. Cancer. 2009;115:1245-1252. [PMID: 19156918 DOI: 10.1002/cncr.24139] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 4.1] [Reference Citation Analysis]
68 Gunvén P. Liver embolizations in oncology: A review: Part I. Arterial (chemo)embolizations. Med Oncol 2008;25:1-11. [DOI: 10.1007/s12032-007-0039-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
69 Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, Fallon J, Mandeli J, Woo SL. Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 2009;16:266-78. [PMID: 18846115 DOI: 10.1038/cgt.2008.74] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
70 Tajiri H, Takano T, Tanaka H, Ushijima K, Inui A, Miyoshi Y, Ozono K, Abukawa D, Endo T, Brooks S, Tanaka Y. Hepatocellular carcinoma in children and young patients with chronic HBV infection and the usefulness of alpha-fetoprotein assessment. Cancer Med 2016;5:3102-10. [PMID: 27748053 DOI: 10.1002/cam4.917] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
71 Murakami E, Aikata H, Miyaki D, Nagaoki Y, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Takahashi S. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012;42:442-453. [PMID: 22176468 DOI: 10.1111/j.1872-034x.2011.00943.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
72 Lee JH, Yoon JH, Yu SJ, Chung GE, Jung EU, Kim HY, Kim BH, Choi DH, Myung SJ, Kim YJ, Kim CY, Lee HS. Retinoic acid and its binding protein modulate apoptotic signals in hypoxic hepatocellular carcinoma cells. Cancer Lett 2010;295:229-35. [PMID: 20350780 DOI: 10.1016/j.canlet.2010.03.005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
73 Jeong Y, Yoon SM, Han S, Shim JH, Kim KM, Lim YS, Lee HC, Kim SY, Park JH, Lee SW, Ahn SD, Choi EK, Kim JH. Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. PLoS One. 2015;10:e0135298. [PMID: 26252472 DOI: 10.1371/journal.pone.0135298] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
74 Wei M, Chen S, Li J, Li B, Shen J, Peng Z, Zhou Q, Zou Y, He X, Li S, Li D, Peng B, Lai J, Peng S, Qin B, Kuang M. Prognostic Role of Time to Surgery in Hepatocellular Carcinoma at Barcelona Clinic Liver Cancer Stage 0-A. Ann Surg Oncol 2020;27:3740-53. [PMID: 32424586 DOI: 10.1245/s10434-020-08499-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Zheng H, Ke X, Li D, Wang Q, Wang J, Liu X, Deng M, Deng X, Xue Y, Zhu Y, Wang Q. NEDD4 promotes cell growth and motility in hepatocellular carcinoma. Cell Cycle 2018;17:728-38. [PMID: 29480061 DOI: 10.1080/15384101.2018.1440879] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
76 Siriwardana RC, Lo CM, Chan SC, Fan ST. Role of portal vein embolization in hepatocellular carcinoma management and its effect on recurrence: a case-control study. World J Surg 2012;36:1640-6. [PMID: 22411084 DOI: 10.1007/s00268-012-1522-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
77 Kodama H, Aikata H, Murakami E, Miyaki D, Nagaoki Y, Hashimoto Y, Azakami T, Katamura Y, Kawaoka T, Takaki S, Hiramatsu A, Waki K, Imamura M, Kawakami Y, Takahashi S, Ishikawa M, Kakizawa H, Awai K, Kenjo M, Nagata Y, Chayama K. Clinical outcome of esophageal varices after hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with major portal vein tumor thrombus. Hepatol Res 2011;41:1046-56. [PMID: 22032677 DOI: 10.1111/j.1872-034X.2011.00857.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
78 Qin LX. Inflammatory immune responses in tumor microenvironment and metastasis of hepatocellular carcinoma. Cancer Microenviron. 2012;5:203-209. [PMID: 22678823 DOI: 10.1007/s12307-012-0111-1] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 4.0] [Reference Citation Analysis]
79 Kanhere HA, Leopardi LN, Fischer L, Kitchener MI, Maddern GJ. TREATMENT OF UNRESECTABLE HEPATOCELLULAR CARCINOMA WITH RADIOLABELLED LIPIODOL. ANZ J Surg 2008;78:371-6. [DOI: 10.1111/j.1445-2197.2008.04480.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
80 Liao Y, Zheng Y, He W, Li Q, Shen J, Hong J, Zou R, Qiu J, Li B, Yuan Y. Sorafenib therapy following resection prolongs disease-free survival in patients with advanced hepatocellular carcinoma at a high risk of recurrence. Oncol Lett 2017;13:984-92. [PMID: 28356989 DOI: 10.3892/ol.2016.5525] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
81 Yang MY, Jeong SW, Kim DK, Kim SG, Jang JY, Kim YS, Lee JS, Kim BS, Kim JH, Kim YJ. Treatment of hepatocellular carcinoma with portal vein thrombosis by sorafenib combined with hepatic arterial infusion chemotherapy. Gut Liver. 2010;4:423-427. [PMID: 20981227 DOI: 10.5009/gnl.2010.4.3.423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
82 Lo YC, Hsu FC, Hung SK, Tseng KC, Hsieh YH, Lee MS, Tseng CW, Lin HY, Chen LC, Chiou WY. Prognosticators of hepatocellular carcinoma with intrahepatic vascular invasion. Ci Ji Yi Xue Za Zhi 2019;31:40-6. [PMID: 30692831 DOI: 10.4103/tcmj.tcmj_14_18] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Park HK, Lee SS, Im CB, Im C, Cha RR, Kim WS, Cho HC, Lee JM, Kim HJ, Kim TH, Jung WT, Lee OJ. Hepatitis C virus genotype affects survival in patients with hepatocellular carcinoma. BMC Cancer 2019;19:822. [PMID: 31429755 DOI: 10.1186/s12885-019-6040-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
84 Chang Y, Lairson DR, Chan W, Lu S, Aoki N. Cost-effectiveness of screening for hepatocellular carcinoma among subjects at different levels of risk: Cost-effectiveness of screening for HCC. Journal of Evaluation in Clinical Practice 2011;17:261-7. [DOI: 10.1111/j.1365-2753.2010.01432.x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
85 Zhu K, Meng X, Zhou B, Qian J, Huang W, Deng M, Shan H. Percutaneous transsplenic portal vein catheterization: technical procedures, safety, and clinical applications. J Vasc Interv Radiol. 2013;24:518-527. [PMID: 23522157 DOI: 10.1016/j.jvir.2012.12.028] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
86 Gao L, Wang XD, Niu YY, Duan DD, Yang X, Hao J, Zhu CH, Chen D, Wang KX, Qin XM, Wu XZ. Molecular targets of Chinese herbs: a clinical study of hepatoma based on network pharmacology. Sci Rep 2016;6:24944. [PMID: 27143508 DOI: 10.1038/srep24944] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 6.8] [Reference Citation Analysis]
87 Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, Pillai AA, Kim HS. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol. 2015;30:1167-1174. [PMID: 25675849 DOI: 10.1111/jgh.12920] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
88 Andersson KL, Salomon JA, Goldie SJ, Chung RT. Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol. 2008;6:1418-1424. [PMID: 18848905 DOI: 10.1016/j.cgh.2008.08.005] [Cited by in Crossref: 139] [Cited by in F6Publishing: 118] [Article Influence: 9.9] [Reference Citation Analysis]
89 Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009;5:889-899. [PMID: 19663737 DOI: 10.2217/fon.09.64] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
90 Nam JY, Lee YB, Lee JH, Yu SJ, Kim HC, Chung JW, Yoon JH, Kim YJ. A Prognostic Prediction Model of Transarterial Radioembolization in Hepatocellular Carcinoma: SNAP-HCC. Dig Dis Sci 2021. [PMID: 33538921 DOI: 10.1007/s10620-021-06843-4] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Chen CP, Haas-kogan D. Neoplasms of the hepatobiliary system: clinical presentation, molecular pathways and diagnostics. Expert Review of Molecular Diagnostics 2014;10:883-95. [DOI: 10.1586/erm.10.76] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
92 Eom BW, Lee JH, Lee JS, Kim MJ, Ryu KW, Choi IJ, Cho SJ, Lee JY, Rhee J, Nam BH, Kim YW. Survival analysis of gastric cancer patients with tumor thrombus in the portal vein. J Surg Oncol 2012;105:310-5. [PMID: 21898415 DOI: 10.1002/jso.22083] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
93 Dhar VK, Kim Y, Wima K, Hoehn RS, Shah SA. The Importance of Safety-Net Hospitals in Emergency General Surgery. J Gastrointest Surg 2018;22:2064-71. [PMID: 30039448 DOI: 10.1007/s11605-018-3885-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
94 Hsu C, Shen Y, Cheng C, Hu F, Cheng A. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials 2010;31:55-61. [DOI: 10.1016/j.cct.2009.08.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
95 Zhou B, Yan Z, Liu R, Shi P, Qian S, Qu X, Zhu L, Zhang W, Wang J. Prospective Study of Transcatheter Arterial Chemoembolization (TACE) with Ginsenoside Rg3 versus TACE Alone for the Treatment of Patients with Advanced Hepatocellular Carcinoma. Radiology 2016;280:630-9. [PMID: 26885681 DOI: 10.1148/radiol.2016150719] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 5.7] [Reference Citation Analysis]
96 Chung GE, Lee JH, Yoon JH, Myung SJ, Lee K, Jang JJ, Lee JM, Kim SH, Suh KS, Kim YJ. Prognostic implications of tumor vascularity and its relationship to cytokeratin 19 expression in patients with hepatocellular carcinoma. Abdom Imaging. 2012;37:439-446. [PMID: 21584634 DOI: 10.1007/s00261-011-9756-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]